Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma

Inclusion Criteria: * \< 21 years of age at original diagnosis * histological verification of low grade glioma (glial tumors, neuronal tumors or chiasmatic-hypothalamic tumor) at original diagnosis * evidence of tumor recurrence or progression by MRI or contrast CT * Karnofsky and Lansky performance status of 0,1 or 2 * life expectancy of greater than or equal to 2 months * adequate organ and bone marrow function within 7 days of starting treatment with Vinblastine * absolute neutrophil count (ANC)\> 1000/uL * platelet count \> 100,000/uL (transfusion independent) * serum creatinine \< 1.5 x normal for age * written informed consent signed by subject and/or subject's parent/legal guardian Exclusion Criteria: * not recovered from the acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy * chemotherapy within 2 weeks of entry in study (4 weeks if prior nitrosourea was used) * less than 7 days since the completion of therapy with a biologic agent * less than 2 months since cranial/spinal radiation * receiving a stable dose of dexamethasone for less than one week